A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer - Trial NCT06233864
Access comprehensive clinical trial information for NCT06233864 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 63 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
Phase 2
Mar 01, 2024
May 01, 2026
Primary Outcome
Object Response Rate, ORR
Summary
This is a phase 2 clinical study,to explore the efficacy and safety of Disitamab Vedotin in
 patients with locally advanced or metastatic pancreatic cancer expressing HER2.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06233864
Non-Device Trial